Unexpected lack of effect of the rifampin-induced P-glycoprotein on the oral bioavailability of its substrate, talinolol, in humans: Implication in phenotyping

被引：4
|
作者：
Chiou, WL [1 ]
Ma, C [1 ]
Wu, TC [1 ]
Jeong, HY [1 ]
机构：
[1] Univ Illinois, Coll Pharm, Dept Pharmaceut & Phamacodynam, Chicago, IL 60612 USA
来源：
JOURNAL OF PHARMACEUTICAL SCIENCES | 2003年 / 92卷 / 01期
关键词：
D O I：
10.1002/jps.10261
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
引用
收藏
页码：4 / 7
页数：4
相关论文
共 31 条
  • [1] Unexpected lack of effect of the rifampin-induced P-glycoprotein on the oral bioavailability of its substrate, talinolol, in humans: Implication in phenotyping - Reply
    Siegmund, W
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2003, 92 (01) : 8 - 9
  • [2] P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans
    Schwarz, UI
    Gramatté, T
    Krappweis, J
    Oertel, R
    Kirch, W
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2000, 38 (04) : 161 - 167
  • [3] Unexpected effect of verapamil on oral bioavailability of the β-blocker talinolol in humans
    Schwarz, UI
    Gramatté, T
    Krappweis, J
    Berndt, A
    Oertel, R
    von Richter, O
    Kirch, W
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (03) : 283 - 290
  • [4] Unexpected verapamil effect on oral bioavailability of the β-blocker talinolol in humans
    Schwarz, U
    Krappweis, J
    Berndt, A
    Gramatté, T
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1998, 357 (04) : R167 - R167
  • [5] Pre-clinical Evidence of Enhanced Oral Bioavailability of the P-Glycoprotein Substrate Talinolol in Combination with Morin
    Pathak, Shriram M.
    Udupa, N.
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2010, 31 (2-3) : 202 - 214
  • [6] Lack of effect of continuous glycyrrhizin administration on the pharmacokinetics of the P-glycoprotein substrate talinolol in healthy volunteers
    Yan, Miao
    Fang, Ping-Fei
    Li, Huan-De
    Xu, Ping
    Liu, Yi-Ping
    Wang, Feng
    Cai, Hua-Lin
    Tan, Qin-You
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 69 (03) : 515 - 521
  • [7] Oral bioavailability of digoxin is enhanced by talinolol: Evidence for involvement of intestinal P-glycoprotein
    Westphal, K
    Weinbrenner, A
    Giessmann, T
    Stuhr, M
    Franke, G
    Zschiesche, M
    Oertel, R
    Terhaag, B
    Kroemer, HK
    Siegmund, W
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 68 (01) : 6 - 12
  • [8] Lack of effect of continuous glycyrrhizin administration on the pharmacokinetics of the P-glycoprotein substrate talinolol in healthy volunteers
    Miao Yan
    Ping-Fei Fang
    Huan-De Li
    Ping Xu
    Yi-Ping Liu
    Feng Wang
    Hua-Lin Cai
    Qin-You Tan
    European Journal of Clinical Pharmacology, 2013, 69 : 515 - 521
  • [9] An alternative hypothesis to involvement of intestinal P-glycoprotein as the cause for digoxin oral bioavailability enhancement by talinolol
    Chiou, WL
    Ma, C
    Chung, SM
    Wu, TC
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (01) : 79 - 80
  • [10] Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol
    Schwarz, U. I.
    Hanso, H.
    Oertel, R.
    Miehlke, S.
    Kuhlisch, E.
    Glaeser, H.
    Hitzl, M.
    Dresser, G. K.
    Kim, R. B.
    Kirch, W.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (05) : 669 - 678
1234